TY - JOUR
T1 - Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration
AU - Muñoz, Monica A.
AU - Delcher, Chris
AU - Dal Pan, Gerald J.
AU - Kortepeter, Cindy M.
AU - Wu, Eileen
AU - Wei, Yu Jung Jenny
AU - Xiao, Hong
AU - Winterstein, Almut G.
N1 - Publisher Copyright:
© 2019 Pharmacotherapy Publications, Inc.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Study Objective: Consumers and healthcare professionals can voluntarily report adverse experiences associated with drug products to the United States Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS). Consumers and healthcare professionals used the same general voluntary reporting form (GVR) until mid-2013, when a consumer voluntary reporting form (ConVR), written in plain language, was implemented. The objective of this study was to examine the effect of the ConVR on the quality and quantity of consumer reports submitted directly to FAERS. Design: Descriptive; quasi-experimental. Data Source: FAERS database. Measurements and Main Results: We identified all consumer and healthcare professional reports received directly by the FDA from January 1, 2011, through December 31, 2015. Report quality was defined by the completeness of 15 individual data fields and a structured tool measuring clinical documentation. An interrupted time series design was used to evaluate the impact on the quantity of consumer reports. Consumer reports submitted on the ConVR generally included more patient, product, and event data in the structured data fields than those submitted on the GVR. Fields with the greatest absolute percentage difference after the ConVR was introduced included race/ethnicity (+77.2%), product start and stop dates (+43% and +40.3%, respectively), dechallenge and rechallenge information (+19.1% and +29.4%, respectively), and medical history (+27%). Our structured assessment also classified more reports received on the ConVR as well documented relative to the GVR consumer reports (64.9% vs 37.8%, p<0.01). The time series model demonstrated an immediate increase of 499 consumer reports in the month following the ConVR's implementation (p<0.01). Conclusion: Our findings suggest that the ConVR has contributed positively to both the quality and quantity of consumer reports in FAERS.
AB - Study Objective: Consumers and healthcare professionals can voluntarily report adverse experiences associated with drug products to the United States Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS). Consumers and healthcare professionals used the same general voluntary reporting form (GVR) until mid-2013, when a consumer voluntary reporting form (ConVR), written in plain language, was implemented. The objective of this study was to examine the effect of the ConVR on the quality and quantity of consumer reports submitted directly to FAERS. Design: Descriptive; quasi-experimental. Data Source: FAERS database. Measurements and Main Results: We identified all consumer and healthcare professional reports received directly by the FDA from January 1, 2011, through December 31, 2015. Report quality was defined by the completeness of 15 individual data fields and a structured tool measuring clinical documentation. An interrupted time series design was used to evaluate the impact on the quantity of consumer reports. Consumer reports submitted on the ConVR generally included more patient, product, and event data in the structured data fields than those submitted on the GVR. Fields with the greatest absolute percentage difference after the ConVR was introduced included race/ethnicity (+77.2%), product start and stop dates (+43% and +40.3%, respectively), dechallenge and rechallenge information (+19.1% and +29.4%, respectively), and medical history (+27%). Our structured assessment also classified more reports received on the ConVR as well documented relative to the GVR consumer reports (64.9% vs 37.8%, p<0.01). The time series model demonstrated an immediate increase of 499 consumer reports in the month following the ConVR's implementation (p<0.01). Conclusion: Our findings suggest that the ConVR has contributed positively to both the quality and quantity of consumer reports in FAERS.
KW - FDA Adverse Event Reporting System
KW - adverse drug reaction reporting systems
KW - community participation
KW - drug-related side effects and adverse reactions
KW - postmarketing product surveillance
UR - http://www.scopus.com/inward/record.url?scp=85074043810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074043810&partnerID=8YFLogxK
U2 - 10.1002/phar.2325
DO - 10.1002/phar.2325
M3 - Article
C2 - 31479525
AN - SCOPUS:85074043810
SN - 0277-0008
VL - 39
SP - 1042
EP - 1052
JO - Pharmacotherapy
JF - Pharmacotherapy
IS - 11
ER -